A recent study documented blood transcriptional profiles in pediatric patients with systemic lupus erythematosus (SLE), finding that plasmablast signatures were the most robust biomarker of SLE disease activity. Researchers were further able to stratify patients into groups on the basis of molecular correlates, which may aid in personalizing SLE treatment and identifying biomarkers that can predict occurrence and frequency of flares…
